Ann: Bod Science announces placement to raise A$2m, page-49

I believe there’s a lack of clarity on what can be sold in the UK even with the novel food application so I don’t believe we’re actively selling over there but happy to be proven wrong on this.

Agree the estimates are blue sky but there’s +$250m AUD p.a currently being spent in Aus for CBD with a prescription across all indications. Sleep formula or not, it’s highly bioavailable CBD and I’d be surprised if at the very least one tenth (half of what I stated above) of those already taking it for any condition don’t start getting it OTC to avoid the hassle of doctor’s prescriptions. Then not to mention those who may start using it as a result of not having to go through a doctor but don’t use it currently.

100% market share if all goes well initially, with the next closest competitor (either Emyria or Avecho) at the very least 6-12 months behind us.